NAV

Mizolastine

Enzymes (1)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mizolastine
Accession Number
DB12523
Description

Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
3D
Similar Structures
Weight
Average: 432.503
Monoisotopic: 432.207387612
Chemical Formula
C24H25FN6O
Synonyms
  • Mizolastina
  • Mizolastine
  • Mizolastinum
External IDs
  • CCRIS 8410
  • SL 85.0324

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Mizolastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Mizolastine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Mizolastine.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Mizolastine.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Mizolastine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Mizolastine.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Mizolastine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Mizolastine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Mizolastine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Mizolastine.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Mizolastine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Mizollen

Categories

ATC Codes
R06AX25 — Mizolastine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Not Available
Direct Parent
Benzimidazoles
Alternative Parents
Dialkylarylamines / Hydroxypyrimidines / Fluorobenzenes / Aminopyrimidines and derivatives / Piperidines / N-substituted imidazoles / Aryl fluorides / Aminoimidazoles / Heteroaromatic compounds / Azacyclic compounds
show 4 more
Substituents
Aminoimidazole / Aminopyrimidine / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Azole / Benzenoid / Benzimidazole / Dialkylarylamine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
244O1F90NA
CAS number
108612-45-9
InChI Key
PVLJETXTTWAYEW-UHFFFAOYSA-N
InChI
InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
IUPAC Name
2-[(1-{1-[(4-fluorophenyl)methyl]-1H-1,3-benzodiazol-2-yl}piperidin-4-yl)(methyl)amino]-3,4-dihydropyrimidin-4-one
SMILES
CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1

References

General References
  1. EMC Package Leaflet: Mizollen (mizolastine) modified-release tablets [Link]
Human Metabolome Database
HMDB0240233
PubChem Compound
65906
PubChem Substance
347828752
ChemSpider
59315
BindingDB
22877
RxNav
61455
ChEBI
31857
ChEMBL
CHEMBL94454
ZINC
ZINC000013831810
PharmGKB
PA166129535
Wikipedia
Mizolastine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral10 mg
Tablet, extended releaseOral10 mg
Tablet, film coatedOral10 MG
Tablet, delayed releaseOral10 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0893 mg/mLALOGPS
logP3.51ALOGPS
logP3.73ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)8.08ChemAxon
pKa (Strongest Basic)5.63ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area65.76 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity122.28 m3·mol-1ChemAxon
Polarizability46.07 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0011900000-375df4a855e43dfec509
MS/MS Spectrum - , positiveLC-MS/MSsplash10-056s-1924000000-3222d3ee56cb73f00360
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0721900000-53e1c9b1a9ae2a2a816d

Enzymes

Details1. Cytochrome P450 2D6
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Nicolas JM, Whomsley R, Collart P, Roba J: In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79. [PubMed:10597902]
  2. Interactions of the H1 antihistamines [Link]

Drug created on October 20, 2016 16:42 / Updated on October 24, 2020 01:30

Logo pink
DrugBank’s data is machine-learning ready.
Are you?
Our datasets are structured and curated allowing you to explore different algorithms, approaches and features. Learn More.